We, therefore, believe that studies on the expression of both ALK and CD30 in breast carcinoma are still necessary, given the potential benefit of targeted therapy on breast cancers with aggressive biology and poor response to conventional chemotherapeutic regimens. Here, TNFRSF8 is linked to breast carcinoma.